Fellow of the Academy of Medical Sciences

Citryll Announces Appointments of Eduardo Bravo as CEO and Tim Schenk as CBO

Retrieved on: 
Tuesday, August 29, 2023
Biotechnology, Pharmaceutical, Health, SPAC, IPO, Analytical chemistry, Therapy, University, Doctor of Philosophy, Takeda, CSO, Phase II, Erasmus University Rotterdam, Business, MBA, Business administration, EQT, Fellow of the Academy of Medical Sciences, Acquisition, INSEAD, Hidradenitis suppurativa, Janssen Vaccines, Immune-mediated inflammatory diseases, Sanofi, In Ictu Oculi, Johnson & Johnson, TiGenix, Commercial, GSK plc, Rheumatoid arthritis, Janssen Pharmaceuticals, Management, Citryl-CoA lyase

Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo Bravo as Chief Executive Officer.

Key Points: 
  • Citryll , a clinical-stage biotech company developing first-in-class therapeutics to treat immune-mediated inflammatory diseases, today announced the appointment of Eduardo Bravo as Chief Executive Officer.
  • In addition, Citryll has appointed Tim Schenk, Ph.D., as Chief Business Officer.
  • Dr. Schenk brings with him a broad background in business and commercial development across the life sciences industry.
  • As Mr. Bravo steps into the CEO role, Eric Meldrum, Ph.D., will fully resume his position as Chief Scientific Officer at Citryll.

Esperion Presents Two CLEAR Outcomes Study Late-Breakers at European Society of Cardiology Congress 2023

Retrieved on: 
Saturday, August 26, 2023
CV, Shoulder, Diabetes, Life, Splenic infarction, Spasm, Fetus, Lactation, Pregnancy, European Society of Cardiology, Bempedoic acid, Doctor of Philosophy, Pain, Congress, Prediabetes, Patient, Risk, Disease, Gout, Diet, MBBS, Ezetimibe, Drug, Simvastatin, Cardiovascular disease, Pravastatin, Back pain, Fellow of the Academy of Medical Sciences, ESPR, Tablet, ESC, Safety, Rotator cuff, Atrial fibrillation, CVD, Abdominal pain, Uric acid, Anemia, Mortality, Imperial College London, Achilles tendon, Glycated hemoglobin, Bronchitis, Tendon rupture, Monash University, ATP, Rupture, Kidney, NEJM, CLEAR, Moyamoya disease, Upper respiratory tract infection, Health, Dietary supplement, Pharmaceutical industry, MD, Esperies, Hyperuricemia

ANN ARBOR, Mich., Aug. 26, 2023 (GLOBE NEWSWIRE) -- Esperion (NASDAQ: ESPR) today announced the presentation of results from two oral presentations at the Late-Breaking Science Session entitled, “Clinical trial updates on prevention and lipid lowering” at the European Society of Cardiology (ESC) 2023 Congress, taking place August 25-28, 2023, in Amsterdam, Netherlands.

Key Points: 
  • “We are pleased to share additional results from our landmark CLEAR Outcomes study in late-breaker presentations at ESC 2023,” said Sheldon Koenig, President and CEO of Esperion.
  • Of the 13,970 patients included in CLEAR Outcomes, 45.6% had diabetes, 41.5% were pre-diabetic, and 12.9% had normoglycemia.
  • At Esperion, we discover, develop, and commercialize innovative medicines to help improve outcomes for patients with or at risk for cardiovascular and cardiometabolic diseases.
  • CLEAR Outcomes is part of the CLEAR clinical research program for NEXLETOL® (bempedoic acid) Tablet and NEXLIZET® (bempedoic acid and ezetimibe) Tablet.

Element Biosciences Establishes Scientific Advisory Board

Retrieved on: 
Monday, August 14, 2023
SAB, Stanford Cancer Institute, Fellow of the Royal Society, University, UCSB Physics Department, Stanford University, Medicine, Cancer research, Wellcome Sanger Institute, Eye, United States Air Force Scientific Advisory Board, RNA, Research, Genomics, Wolf Prize in Chemistry, Fellow of the Academy of Medical Sciences, Doctor of Philosophy, Associate, Biochemistry, Regenerative medicine, Molecular biology, Stanford University School of Medicine, EMBO, MD, SAN, Structural biology, Element, Biology, Science, SVP, Royal Society, Childhood cancer, Vaccine, Management, Pharmaceutical industry, Chemistry

SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.

Key Points: 
  • SAN DIEGO, Aug. 14, 2023 /PRNewswire/ -- Element Biosciences, Inc., developer of the Element AVITI System, an innovative DNA sequencing platform that is disrupting the genomics industry, today announced the formation of its Scientific Advisory Board with four leading experts on genomics, oncology, chemistry, and biology.
  • Element's Scientific Advisory Board will provide guidance and direction for research, development, and product innovation as the company continues its success and expansion in the genomics industry.
  • "With this diverse and accomplished group of scientists from across the globe, our Scientific Advisory Board empowers us to reach new heights in research and product innovation," said Michael Previte, PhD, Element CTO, SVP of R&D, and co-founder.
  • "I am thrilled to lead Element's Scientific Advisory Board," said Joseph (Jody) Puglisi, Jauch Professor in the Department of Structural Biology at Stanford University School of Medicine and Element's Scientific Advisory Board chair.

Candel Therapeutics Reports Second Quarter 2023 Financial Results and Recent Corporate Highlights

Retrieved on: 
Thursday, August 10, 2023
Injection, Insurance, Gene, Survival, Clinical trial, Nestin, NSCLC, SOC, Lung cancer, American Society of Gene and Cell Therapy, Pharmacist, ASCO, Development, American Society of Clinical Oncology, MD, Patient, Standard of care, Administration, HGG, Annual general meeting, Cell, Research, MOS, Break, Therapy, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Society, Food, Pharmaceutical industry, Video game, Candel, Doctor of Philosophy, Fellow of the Academy of Medical Sciences, Q4

NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.

Key Points: 
  • NEEDHAM, Mass., Aug. 10, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today reported financial results for the second quarter ended June 30, 2023, and provided a corporate update.
  • Research and Development Expenses: Research and development expenses were $5.9 million for the second quarter of 2023 compared to $5.0 million for the second quarter of 2022.
  • General and Administrative Expenses: General and administrative expenses were $3.6 million for the second quarter of 2023 compared to $3.8 million for the second quarter of 2022.
  • General and administrative expenses included non-cash stock compensation expense of $0.4 million for both the second quarter of 2023 and the second quarter of 2022.

Brainomix AI Technology Improves Access to Stroke Treatment across the NHS

Retrieved on: 
Tuesday, August 8, 2023
Communication, CT, A&E, Oxford, Disability, Stroke, Innovation, Brain, Oxford University Hospitals NHS Foundation Trust, OXFORD, Thrombectomy, MRI, Hospital, Patient, NHS Long Term Plan, Artificial intelligence, ISDN, AI, NHS, Oxford University Press, Software, Pharmaceutical industry, Medical imaging, Nursing, Health, Fellow of the Academy of Medical Sciences

Prompt recognition of this type of stroke and transfer to specialist centres for treatment is vital to ensure best possible outcomes for patients.

Key Points: 
  • Prompt recognition of this type of stroke and transfer to specialist centres for treatment is vital to ensure best possible outcomes for patients.
  • After Brainomix secured the NHS AI in Health and Care Award in 2020, the Oxford AHSN supported the spread and adoption of e-Stroke through participating Integrated Stroke Delivery Networks (ISDNs).
  • Feedback from NHS colleagues reported that the software is helping them to deliver a more efficient and effective stroke services for their patients.
  • We look forward to seeing more results as they come out, building on the largest real-world and independent evaluation of a stroke AI imaging platform."

Adrestia Acquired by Insmed Incorporated, Bringing its Novel Approach to Tackling Intractable Genetic Diseases to Insmed’s Early-Stage Research Portfolio

Retrieved on: 
Thursday, August 3, 2023
Science, Professional Services, Research, Finance, Cambridge Institute for Sustainability Leadership, Molecular biology, GSK, LLP, University, Genetics, Cancer research, University of Cambridge, Cancer, General partnership, Acquisition, Patient, FRS, Cancer Research UK, Drug discovery, Therapy, Gene, Oligonucleotide, DSM-IV codes, Genome, Pharmaceutical industry, Ahrén, Adrasteia, Insming, Biology, Fellow of the Academy of Medical Sciences

“Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.

Key Points: 
  • “Our acquisition by Insmed enables us to scale up our research beyond what was possible as a standalone company.
  • With Insmed, we’re no longer dreaming big, we’re going big.”
    Adrestia’s synthetic rescue platform uses whole genome assays to identify drug targets for genetic diseases in a wide network of functionally connected genes.
  • Sir Steve is University of Cambridge Professor of Biology and Senior Group Leader at the Cancer Research UK Cambridge Institute.
  • J.P. Morgan Securities plc acted as exclusive financial adviser to Adrestia, and Goodwin Procter (UK) LLP acted as Adrestia’s legal counsel.

Candel Therapeutics to Participate in the Canaccord Genuity 43rd Annual Growth Conference

Retrieved on: 
Wednesday, August 2, 2023
Candel, Canaccord Genuity, Doctor of Philosophy, MD, Patient, Webcast, Therapy, CADL, Conference, News, Pharmaceutical industry, Broadcasting, Fellow of the Academy of Medical Sciences

NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023, in Boston.

Key Points: 
  • NEEDHAM, Mass., Aug. 02, 2023 (GLOBE NEWSWIRE) -- Candel Therapeutics, Inc. (Candel or the Company) (Nasdaq: CADL), a clinical stage biopharmaceutical company focused on developing viral immunotherapies to help patients fight cancer, today announced that Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer, will participate in a fireside chat at the upcoming Canaccord Genuity 43rd Annual Growth Conference, taking place August 7-10, 2023, in Boston.
  • A live webcast of the session will be available by selecting Events and Presentations under the News & Events tab in the Investors section on Candeltx.com .
  • A replay of the webcast will be archived for up to 90 days following the session date.

Alentis Therapeutics Appoints Prof. David Jayne and Prof. Josep Tabernero to its Scientific Advisory Board

Retrieved on: 
Wednesday, June 21, 2023
Research, Clinical Trials, Biotechnology, Other Health, Health, Pharmaceutical, Other Science, Science, Oncology, American Society of Nephrology, AACR, University, Therapy, European Renal Association, Vall, Nephrology, Neoplasm, University of Vic - Central University of Catalonia, University of Cambridge, ESMO, Editorial, Coronavirus Scientific Advisory Board, Editorial Board at The Wall Street Journal, Multimedia, Doctor of Philosophy, Teaching hospital, ASCO, Professor, ANCA, Patient, CLDN1, Renal Association, Vasculitis, Society, Safety, Pharmaceutical industry, Medicine, Fellow of the Academy of Medical Sciences, MD

Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Professor David Jayne, Professor of Clinical Autoimmunity at Cambridge University and Professor Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital as members of its Scientific Advisory Board.

Key Points: 
  • Alentis Therapeutics (“Alentis”), the clinical-stage biotechnology company developing treatments for Claudin-1 positive (CLDN1+) tumors and organ fibrosis, announced today the appointment of Professor David Jayne, Professor of Clinical Autoimmunity at Cambridge University and Professor Josep Tabernero, Head of Medical Oncology at Vall d’Hebron University Hospital as members of its Scientific Advisory Board.
  • View the full release here: https://www.businesswire.com/news/home/20230621207738/en/
    Dr David Jayne (left) and Dr Josep Tabernero (right) (Photo: Business Wire)
    “We are delighted to welcome David and Josep to our newly formed Scientific Advisory Board,” said Dr. Luigi Manenti, Chief Medical Officer of Alentis.
  • Dr. Jayne is the international leader in the area of clinical research in anti-neutrophil cytoplasm antibody (ANCA)-associated vasculitis.
  • Dr. David Jayne, Prof. of Clinical Autoimmunity at Cambridge University said: “I have spent the last 25 years investigating new treatments for ANCA-Vasculitis.

Candel Therapeutics Announces It Expects to Report Topline Data from its Phase 2 Clinical Trial of CAN-2409 in Non-Small Cell Lung Cancer in the Second Quarter of 2024

Retrieved on: 
Tuesday, June 13, 2023
ICI, Cohort, Survival, Clinical trial, Fast Track, NSCLC, Lung cancer, Doctor of Philosophy, ASCO, MD, Patient, Data, Aggarwal, Neoplasm, Therapy, CADL, Regulation of food and dietary supplements by the U.S. Food and Drug Administration, Valaciclovir, Food, Pharmaceutical industry, Candel, Fellow of the Academy of Medical Sciences

“In conjunction with this topline data, we will assess whether the effect on tumor biology previously reported could translate into improved survival, which we believe is what matters to patients and regulators.

Key Points: 
  • “In conjunction with this topline data, we will assess whether the effect on tumor biology previously reported could translate into improved survival, which we believe is what matters to patients and regulators.
  • These data supported the application for Fast Track designation, granted by the U.S. Food and Drug Administration for this program in April 2023 .
  • The Company remains on target to present additional clinical and immunological biomarker activity data in the third quarter of 2023.
  • CAN-2409 is an investigational off-the-shelf viral immunotherapy designed to induce an individualized, systemic immune response against the patient’s specific tumor.

Candel Therapeutics Appoints Experienced Manufacturing Leader Nicoletta Loggia, PhD, RPh to its Board of Directors

Retrieved on: 
Thursday, June 8, 2023
Drug development, University, Gene, CMC, Survival, Quality of life, AAV, Pharmacist, Lentivirus, Novartis, MD, Patient, Cell, University of Pavia, Therapy, CADL, Prostate cancer, Orchard, Candel, Doctor of Philosophy, Fellow of the Academy of Medical Sciences

“We are pleased to welcome Nicoletta as a new member of Candel’s Board,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) of Candel.

Key Points: 
  • “We are pleased to welcome Nicoletta as a new member of Candel’s Board,” said Paul Peter Tak, MD, PhD, FMedSci, President and Chief Executive Officer (CEO) of Candel.
  • “Her wealth of strategic and hands-on industry experience in drug development and manufacturing makes her an important addition to our Board as we advance our late-stage oncology programs.
  • She oversaw the integration of the CAR-T teams and AveXis’ AAV technical capabilities into Novartis’ technical research and development.
  • She is also a registered pharmacist and member of the UK Royal and Italian Pharmaceutical societies.